Worth Venture Partners’s NeuroOne Medical Technologies NMTC Stock Holding History

Worth Venture Partners’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,161	Closed	-$211K	–	158
2021 Q4	$211K	Buy	+18,161	New	+$294K	0.1%	102

Other funds holding NMTC

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DWM

Drive Wealth Management Lehi, Utah $561M AUM 33.14% 1-Year Est. Return

Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Worth Venture Partners's NMTC Position: Q1 2022 in Review

Worth Venture Partners sold out of NeuroOne Medical Technologies (NMTC) in Q1 2022, closing a stake of 18,161 shares — an estimated $211K sold.

Worth Venture Partners first reported a position in NMTC in Q4 2021 and held it in 1 quarter. The position peaked at $211K in Q4 2021. 11 funds tracked by Wall St. Rank hold NMTC as of Q1 2022.

Worth Venture Partners reported no remaining NeuroOne Medical Technologies position as of Q1 2022 after selling out during the quarter.
Worth Venture Partners sold 18,161 NeuroOne Medical Technologies shares in Q1 2022, an estimated $211K.
Worth Venture Partners first reported a position in NeuroOne Medical Technologies in Q4 2021 and held it in 1 quarter.
Worth Venture Partners's NeuroOne Medical Technologies position peaked at $211K in Q4 2021.
11 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2022.

Based on Worth Venture Partners's 13F filing for Q1 2022, filed 16 May 2022.